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Insulin-like growth factor binding protein 4 (lGFBP-4) 
is a 24·kDa protein that binds insulin·like growth factor 
1 (lGF-l) and IGF·2 with high affinity and inhibits IGF 
action in vitro. We recently described a protease pro-
duced by the BI04 neuronal cell line that cleaves IG-
FBP-4, yielding an approximate 16·kDa immunoreactive 
protein that binds IGFs with reduced affinity. We ana-
lyzed fragments produced by exposing pure IGFBP·4 to 
the protease to determine potential cleavage sites. Elec-
trospray mass spectrometry and amino acid sequencing 
indicated the 16-kDa fragment spanned the NH2 termi-
nus of native IGFBP-4 through Lys-120. There was evi-
dence for an additional proteolytic fragment beginning 
at amino acid 132 and continuing to the COOH terminus. 
Proteolysis could be blocked by a synthetic peptide that 
spanned amino acids 117-126 but not by peptides that 
contained flanking sequences 111-120 or 125-135. Mu-
tagenesis was used to alter the basic residue at position 
120. The expressed mutant IGFBP-4 (KI20A) was rela-
tively resistant to cleavage, strongly suggesting that res-
idues 120-121 represent the cleavage site. This region of 
IGFBP·4 is not homologous with other IGFBPs, explain-
ing the apparent specificity of the protease for IGFBP·4. 
The 16·kDa IGFBP-4 fragment no longer inhibited IGF· 
I-stimulated thymidine uptake in vitro, suggesting that 
proteolytic processing of IGFBP-4 may have important 
functional consequences in vivo. 
The insulin-like growth factors (IGFs)l are mitogens pro-
duced by many tissues and are postulated to act in a paracrinel 
autocrine manner (1). IGF action is thought to be greatly in-
fluenced by the IGF binding proteins (lGFBPs), a family of 
secreted proteins that bind the IGFs with high affinity (2). 
These proteins are expressed by a wide variety of tissues and 
may direct transport of the IGFs into organs. Also, in vitro 
experiments have shown that IGFBPs can either inhibit or 
enhance IGF action depending upon the experimental design 
and the form of IGFBP examined (3-7), suggesting that the 
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IGFBPs modulate local IGF bioactivity in vivo. Six IGFBPs 
have been described (8). Although structurally related, they are 
the products of distinct genes that have differing tissue and 
developmental regulation of expression. Each IGFBP contains 
amino- and carboxyl-terminal regions that are homologous 
among the IGFBPs and rich in cystine or cysteine residues. In 
contrast, the middle third of the molecules is usually free of 
disulfides and has little shared sequence between the various 
IGFBPs. 
All IGFBPs undergo some form of post-translational modifi-
cation. IGFBP-3, -4, -5, and -6 manifest variable degrees of 
glycosylation (8). Phosphorylation ofIGFBP-1 alters its affinity 
for IGFs and biologic actions (9). Recently, extracellular pro-
teolytic processing has emerged as a frequent and potentially 
important mechanism governing the biologic properties of the 
IGFBPs (10-14). The responsible proteases have, in general, 
not been identified, although the IGFBP-3 protease produced 
by human fibroblasts in culture may be a member of the matrix 
metalloprotease family and the IGFBP-3 protease in semi-
nal fluid appears to be prostate-specific antigen (15), a serine 
protease. 
A protease(s) that cleaves IGFBP-4 is present in media of 
cultured fibroblasts (10, 11), decidual cells (16), osteoblasts 
(17-19), and smooth muscle cells (20). An unusual feature is 
that the IGFBP-4 ligand, IGF-1 or -2, greatly accelerates the 
rate of proteolysis when present in the reaction mixture (10, 11, 
16). Although the exact mechanism has not yet been delin-
eated, most data suggest that binding of an IGF by the IG-
FBP-4 makes the latter more susceptible to proteolytic cleav-
age, probably through a conformational change. 
We recently described a glucocorticoid-inducible protease 
produced by the rat B104 neuronal cell line (21). This protease 
cleaves intact 24-kDa IGFBP-4 to a smaller, approximate 16-
kDa species that binds IGFs with a reduced affinity. In order to 
better understand the nature of IGFBP-4 proteolysis, experi-
ments were performed to identify proteolytic cleavage sites 
within the IGFBP-4 molecule and to determine the effect of 
mutagenesis on IGFBP-4 stability. 
EXPERIMENTAL PROCEDURES 
Reagents-The rat IGFBP-4 antibody raised against a synthetic 20-
amino-acid peptide (residues 81-100) was described previously (22). An 
additional rat IGFBP-4 antibody raised against amino acids 111-120 
was provided by N. Ling (Whittier Institute, La Jolla, CAl, along with 
the corresponding synthetic peptide (no. 1). Peptides 2 and 3 (see Fig. 3) 
were synthesized by a commercial vender (Anaspec, San Jose, CAl and 
were judged to be greater than 90% pure. Rat IGFBP-4 was prepared 
from media conditioned by the B104 cell line as described previously 
(21). Restriction endonucleases and molecular biology reagents were 
purchased from New England Biolabs, Beverly, MA. IGF-1 was pro-
vided by Lilly. 
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Radioligand Blots and Immunoblots-Samples were subjected to 
4%/12% discontinuous SDS-polyacrylamide gel electrophoresis and 
electroblotted to nitrocellulose membranes (Schleicher and Schuell). 
Radioligand blotting using 125I_IGF_1 was performed by the method of 
Hossenlopp et al. (23). Immunoblotting was as described previously 
(22). Immunoreactive species were identified by either an avidin-biotin 
alkaline phosphatase conjugate system (Vectastain, Vector Labs, Inc., 
Burlingame, CAl or by chemiluminescent detection (Amersham Corp.). 
Protease Preparation-Media containing the IGFBP-4 protease were 
prepared by dexamethasone treatment of a subline of B104 cells 
(B1040 ,) that produced little IGFBP-4 (24). Cells were grown to conflu-
ency in fetal calf serum-containing media and then switched to serum-
free media containing 100 nM dexamethasone (Sigma). After 2-3 days of 
exposure, harvested media (Dex-media) were centrifuged to remove 
cellular debris and saved at -70°C. When required, conditioned media 
were concentrated using a microconcentrator (Centricon-lO, Amicon, 
Beverly, MA). 
Isolation of IGFBP-4 Fragments-Twenty-five ,.,.g of IGFBP-4 was ex-
posed to the IGFBP-4 protease for 48 h. The pure peptide was incubated 
with 0.5 ml of Dex-media containing 0.1 volume of 0.5 M Tris buffer, pH 
7.4. After 24 h at 37°C, an additional 0.5 ml of media was added followed 
by a final 0.22 rnI12 h later. The reaction mixture was stored frozen and 
subsequently applied to an IGF -1 affinity column (binding capacity, 400-
600 ,.,.g ofIGFBP-4) equilibrated in 0.05 M NaH2P04 , pH 6.6, containing 2 
mM EDTA and 0.1 M NaC!. After 16 h of recirculation, retained IGFBP-4 
was eluted with 0.5 M acetic acid. Fractions containing the immunoreac-
tive 16-kDa IGFBP-4 fragment (determined by irnrnunoblotting) were 
loaded onto a reverse phase HPLC column (C4 Vydac, Hespena, CAl 
equilibrated in 0.04% trifluoroacetic acid and H20. Elution was accom-
plished with a 0-60% CHaCN gradient over 1 h. Fractions were screened 
by immunoblotting, and those containing 16-kDa IGFBP-4 were subjected 
to further analysis. 
Mass Spectrometry-Reverse-phase liquid chromatography fractions 
were evaporated to dryness and then dissolved in water:methanol: 
formic acid (50:50:1, v/v/v). Samples were introduced to a Sciex API III 
triple-quadrupole mass spectrometer (Sciex, Inc., Toronto, Canada) at 4 
,.,.t/min with a syringe pump. The device was equipped with an atmo-
spheric pressure ion source used to sample positive ions produced from 
a pneumatically assisted electrospray interface. Sample ions generated 
by the electrospray process were mass-analyzed by scanning the first 
quadrupole in O.l-atomic mass unit increments over approximately 10 
s and passing mass-selected ions through the second and third quadru-
poles, operated in the radiofrequency-only mode, to a channeltron de-
tector. Mass calibration of the instrument was accomplished just prior 
to sample analysis by matching ions of polypropylene glycol to known 
reference masses stored in the mass calibration table of the mass 
spectrometer. Ten scans were averaged for each analysis. The average 
molecular weights of the sample peptides were calculated from the 
multiply protonated ions in the mass spectrum. 
Amino Acid Sequence Analysis-Automated Edman degradation 
chemistry was used to determine the NH2-terminal protein sequence. 
An Applied Biosystems, Inc. model 470A gas phase sequencer (Foster 
City, CAl was employed for the degradations using the standard se-
quencer cycle, 03RPTH. The respective PTH-derivatives were identified 
by reverse phase HPLC analysis in an on-line fashion employing an 
Applied Biosystems, Inc. model 120A PTH analyzer fitted with a 
Brownlee 2.1-mm (inner diameter) PTH-C18 column. 
Mutagenesis-A full-length IGFBP-4 cDNA in pBluescript SK+ 
(pRBP4-503) served as a template for mutagenesis and was kindly 
provided by Dr. S. Shimasaki of the Whittier Institute (La Jolla, CAl. In 
preparing the mutant IGFBP-4, the unique restriction sites MscI (near 
the lysine 120 codon) and SphI (approximately 200 base pairs 5' to the 
lysine 120 codon) were exploited. An oligonucleotide primer pair was 
synthesized in which the upper primer contained the rat IGFBP-4 
sequence that overlapped the SphI site (5' CTGTGGCTCAGGCAT-
GCGCGGC 3') whereas the lower primer contained the MscI site as well 
as the introduced mutation (5' ACTTTGGCCATATGCGCCTGCAGGC 
3'). These primers were used to generate the 219-base pair DNA frag-
ment by polymerase chain reaction using Vent DNA polymerase (New 
England Biolabs, Beverly, MA). The polymerase chain reaction was run 
for 23 cycles in buffers provided by the manufacturer using a 57°C 
annealing temperature. The product was exposed to SphI and MscI and 
after isolation using agarose gel electrophoresis, ligated back into 
pRBP4-503 from which the matching sequence had been removed by 
enzymatic digestion. Integrity of the mutant was verified by DNA 
sequencing. 
Mammalian Cell Expression and Isolation of Mutant IGFBP-4-The 
mutant IGFBP-4 cDNA was transferred to a pUC 18-based mammalian 
expression vector that utilized a mouse metallothionein promoter 
(pNUT, provided by A. J. D'Ercole, University of North Carolina). 
Chinese hamster ovary cells (CHO K-1) were transfected by the follow-
ing method. The cells were maintained in a-minimal essential medium 
containing 10% fetal calf serum supplemented with penicillin and 
streptomycin. Twenty-four hours before transfection the cells were 
seeded into 6-well tissue culture plates to approximately 15% conflu-
ency. DNA was introduced into the cells by a calcium phosphate pre-
cipitation procedure. The DNA/calcium precipitate was formed by mix-
ing 0.5 ml of 0.25 M calcium chloride containing 10 ,.,.g of plasmid DNA 
in 0.5 ml of 2 x Hanks' basic salt solution. Mter incubation at room 
temperature for 15 min, 200 ,.,.1 (2 ,.,.g of DNA) were applied to the cells 
in 2 ml of medium. Plates were incubated at 37°C for 5 h after which 
calcium-containing media were removed and medium containing 10% 
glycerol was applied for 3 min. After extensive rinsing this medium was 
replaced, and the cells were incubated for 48 h. Treated cells were then 
trypsinized and plated 1:50 in lOO-cm dishes with medium containing 1 
,.,.g/ml methotrexate. Fresh methotrexate was reapplied every 3-4 days 
for 10-12 days when colonies of stably transfected cells began to ap-
pear. Colonies were isolated by cloning rings, trypsinized, and trans-
ferred to individual wells of a 24-well plate. Medium was assayed for 
IGFBP-4 secretion by immunoblotting after the cells reached conflu-
ency. The methotrexate concentration was gradually increased to 50 
,.,.g/ml in the surviving clones. 
Approximately 1 liter of conditioned medium was collected from CHO 
cells expressing the mutant IGFBP-4. The medium was clarified by 
centrifugation at 16,000 x g for 20 min, the pH was adjusted to 6.6 with 
Tris base, and then the medium was loaded at 1 mt/min at 4 °C onto a 
4.4 x 3-cm phenyl-Sepharose column (Pharmacia Biotech Inc.) equili-
brated with 0.05 M sodium phosphate buffer, pH 6.6, containing 0.1 M 
NaCl and 2 mM EDTA. Mter washing, a linear gradient of 0-20% 
CHaCN in 0.05 M sodium phosphate, pH 6.6, 2 mM EDTA was used to 
elute bound proteins. The active fractions were identified by immuno-
blotting and partially lyophilized to remove the CHaCN. The active pool 
was subjected to IGF-1 affinity column chromatography as described 
above. The partially lyophilized eluate was injected onto a Vydac C-4 
reverse phase column (4.6 cm x 15 mm). An isocratic elution with 0.4% 
trifluoroacetic acid was conducted for 10 min followed by a 0-24% 
linear gradient ofCHaCN over 10 min. For the next 20 min the CHaCN 
concentration was increased linearly from 24 to 34% and for the final 24 
min from 34 to 100%. The mutant rat IGFBP-4 eluted as a single peak 
at 28-30% CHaCN. The material was shown to be pure by both immu-
noblotting and ligand blotting. 
Tritiated Thymidine Uptake-B1040, cells were used as targets for 
IGF action. Tritiated thymidine uptake in response to added IGF-1 was 
performed as described previously (24). Cells were exposed to IGF-1 and 
graded concentrations of intact IGFBP-4 or the 16-kDa fragment in 
serum-free media for 24 h prior to the addition of the [aHlthymidine. 
RESULTS 
Characterization of Proteolytic Fragment of IGFBP-4-Pro-
teolytic products of IGFBP-4 were initially examined using 
antibodies directed against specific IGFBP-4 peptide se-
quences. Antisera produced using amino acids 81-100 and 
110-120 of the mature IGFBP-4 molecule both recognize a 
proteolytic fragment of approximately 16 kDa, indicating the 
16-kDa species overlaps, at least in part, amino acids 80-120 
(Fig. 1). Further characterization of the 16-kDa species was 
accomplished by subjecting purified 16-kDa IGFBP-4 (see "Ex-
perimental Procedures") to NH2-terminal amino acid sequence 
analysis and electrospray mass spectrometry (ESMS). The 
amino acid sequence obtained was DEAIH(e)pp(e)S (where 
(e) indicates a possible cysteine), which corresponds to the 
published NH2 terminus of native rat IGFBP-4. Following this, 
the exact molecular weight (Mr ) of the isolated fragment was 
determined by ESMS. Analysis of the data indicated two spe-
cies present in the isolate (Fig. 2); the observed Mr of one 
matches exactly that expected for an IGFBP-4 protein contain-
ing amino acids 1-120 while the other matched with amino 
acids 1-90. Because the 16-kDa IGFBP-4 seen on immunoblot 
reacted with the antibody raised against amino acids 110-120, 
it must represent the 1-120 species. The potential cleavage 
sites are indicated upon the schematic (Fig. 3). 
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FIG. 1. Recognition of proteolytic fragment of IGFBP-4 by an-
tisera raised against differing synthetic peptides. Intact (lanes 1 
and 2) and proteolytically cleaved (lanes 3 and 4) IGFBP-4 were ana-
lyzed by immunoblot using antisera raised against amino acids 81-100 
(lanes 1 and 3) and against amino acids 110-120 (lanes 2 and 4) of 
native IGFBP-4. Immunoblot was developed as described under "Ex-
perimental Procedures." Samples were run without prior di sulfide bond 
reduction. Positions and molecular weight markers are shown to the 
left· 
directed Mutagenesis- The data described suggest a putative 
cleavage site between Lys-120 and His-121. To assess the po-
tential for cleavage at this site, the ability of synthetic peptides 
to inhibit the proteolysis of intact IGFBP-4 was examined. 
Peptides that either spanned or flanked the putative cleavage 
site (see Fig. 3) were incubated at high molar excess with pure 
native IGFBP-4 and Dex-media (Fig. 4). The synthetic peptide 
containing amino acids 117-126 inhibited proteolysis while the 
flanking peptides were ineffective. 
Site-directed mutagenesis was used to alter the IGFBP-4 
molecule, changing the basic lysine at position 120 to alanine. 
The mutant (K120A IGFBP-4) was expressed in CHO cells, 
isolated from conditioned media, and tested for sensitivity to 
proteolytic cleavage. Figs. 5 and 6 show the cleavage over time 
of the K120A IGFBP-4 compared with native IGFBP-4 in the 
presence and absence of IGF-l. Without added IGF-1, proteo-
lytic degradation is minimal (Fig. 5). The addition of IGF-1 
significantly enhanced cleavage of both mutant and native 
IGFBP-4. Although proteolytic cleavage of the mutant IG-
FBP-4 occurred eventually, the appearance of the 16-kDa spe-
cies was significantly delayed compared with wild type IG-
FBP-4. The difference in apparent cleavage rates for native and 
mutant IGFBP-4 was more accurately quantified by incubating 
the purified proteins with the protease and assessing the de-
cline in 24-kDa species over time through Phosphorlmage anal-
ysis of a ligand blot (Fig. 6). This experiment confirmed that the 
proteolytic degradation of K120A IGFBP-4 is slower than that 
of the wild type protein. It also appears that 2B-kDa (glycosyl-
ated) IGFBP-4 is relatively resistant to the protease. 
Examination of the ligand blot data in Fig. 6 suggests greater 
resistance of the mutant to proteolytic cleavage than is appar-
ent in Fig. 5. This likely reflects differences in time of exposure 
to the enzyme (15 versus 24 h) but also may reflect different 
levels of enzymatic activity found in differing batches of condi-
tioned media. In multiple experiments, analyzed by both im-
munoblot and ligand blot, degradation of the K120A mutant 
IGFBP-4 was always attenuated relative to that of the wild 
type, but the amount of intact 24-kDa IGFBP-4 remaining at 
the end of each experiment varied. This is interpreted to mean 
the K120A IGFBP-4 is resistant, but not invulnerable, to cleav-
age by the B104 protease. 
In light of the highly concordant immunologic amino acid 
sequence and ESMS data, substantial cleavage of the mutant 
IGFBP-4 was surprising due to the significant charge change 
expected by substituting alanine at position 120. In order to 
understand this better, the proteolytic fragments from the mu-
tant were analyzed by amino acid sequencing and ESMS. The 
K120A IGFBP-4 was cleaved by exposure to Dex-media in the 
presence of 100 ng/ml IGF-l. The mixture was subjected to 
HPLC as described under "Experimental Procedures," and a 
fraction containing the 16-kDa species was mass-analyzed. De-
convolution of the mass spectra yielded observed Mr of 13,110.3 
± O.B and 11,322.2 ± 0.35 (mean ± S.D. ). The Mr of the larger 
species matches the theoretical sequence from the NH2 termi-
nus through histidine 121 (expected M .. 13,112, accounting for 
the replacement by alanine at position 120). Scanning of the 
IGFBP-4 sequence for a string of amino acids matching the Mr 
of the smaller species yielded a sequence beginning at lysine 
132 and continuing through the carboxyl terminus (expected 
Mr 11,324). In order to verify these data, proteins contained in 
a fraction adjacent to that mass analyzed (also containing the 
16-kDa species by immunoblot) were subjected to NH2-termi-
nal sequence analysis. The data indicated three distinct IG-
FBP-4 sequences. One corresponded to the normal NH2 termi-
nus of intact IGFBP-4. The second began at lysine 132 
(KVVGTPREEPRPVPQ), while the other began with valine 
134 (VXTPREEXXXVXQGS, where X indicates inability to as-
sign a residue for that position). The first two are thus com-
patible with ESMS data for K120A IGFBP-4 peptides of 1-121 
and 132 through the COOH terminus. Concentration of the 
third species may have been too low for detection by ESMS. 
The Effect of Proteolysis on IGFBP-4 Action-In a prior pub-
lication we showed that cleaved IGFBP-4 is capable of binding 
IGF-1 but with reduced affinity (21). In order to determine the 
effect of cleavage on biologic properties of IGFBP-4, the ability 
of intact IGFBP-4 to inhibit IGF-1-stimulated thymidine up-
take was compared with that of cleaved IGFBP-4. The frag-
ment was isolated by HPLC as above. Intact native 24-kDa 
IGFBP-4 produced the expected dose-dependent inhibition of 
IGF-1, using B104 cells as a target (Fig. 7). However, equiva-
lent concentrations of cleaved IGFBP-4 were ineffective, indi-
cating that proteolytic processing ofIGFBP-4 changes its prop-
erties such that it no longer inhibits IGF-1 action. 
DISCUSSION 
Our data indicate that IGFBP-4 is proteolytically cleaved into 
two major fragments following exposure to a protease from B104 
cells. One fragment begins at the NH2 terminus and extends 
through amino acid 120. The other contains residue 132 through 
the COOH terminus. The B104 cell-derived protease appears to 
act at the bond between Lys-120 and His-121 (a trypsin-suscep-
tible site) because proteolysis is blocked by an overlapping syn-
thetic peptide and because mutation oflysine 120 attenuates the 
rate of cleavage. The residues surrounding this putative cleavage 
site (amino acids 116-121) are conserved between the human 
and rat but without a homologous sequence in the other IGFBPs 
(B). This is compatible with the reports of potentially related 
IGFBP-4 proteases from other species that appear to cleave IG-
FBP-4 selectively (10, 11, 16, 1B, 19, 25). 
An IGFBP-4 fragment spanning the NH2 terminus through 
amino acid 90 was also detected by ESMS in one experiment. 
The origin and significance of this species is not clear. It might 
reflect further processing of the 1-120 species and/or be the 
result ofthe action of a distinct protease. Although we could not 
detect a 1-90 species by immunoblotting, in a prior publication 
we observed an appropriate sized fragment when radiolabeled 
IGFBP-4 was exposed to the protease (21). The relative amount 
of that species was very low, and therefore we believe the 1-90 
IGFBP-4 is probably a minor component in the proteolytic 
processing, at least as applied to the B104 system. Fowlkes et 
al. (26) have recently examined the proteolysis of IGFBP-3 in 
human dermal fibroblast medium. They attributed the proteo-
lytic activity to one or more matrix metalloproteinases that 
cleaved IGFBP-3 within its nonhomologous domain. Because 
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FIG. 2. Mass spectrometric analysis of 16-kDa IGFBP-4. The observed and expected M, of two putative fragments and their potential amino 
acid sequences are given in the table at the bottom. N refers to the number of mass determinants for each. Charge states corresponding to the 
species of differing M, are indicated. 
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FIG. 3. Schematic of rat IGFBP-4. Regions of the amino acid ho-
mology among the IGF binding proteins are indicated as shaded boxes . 
The central, nonhomologous sequence is shown using the single alpha-
betic code. The specific sequences of synthetic peptides 1, 2, and 3 are 
indicated by the labeled lines. The underlined amino acids indicate the 
putative N-linked glycosylation site. Amino acid 120 is indicated. The 
asterisk shows potential cleavage sites based on ESMS data. 
cleavage of IGFBP-3 does not occur in B104 conditioned media 
(21), the B104 protease is unlikely to be identical to those 
described by Fowlkes et al. (26). However, recognition of amino 
acid sequences within the nonhomologous regions of the IG-
FBPs by IGFBP proteases could be a general mechanism to 
explain specificity among the IGFBP proteases. 
The single amino acid substitution we introduced was insuf-
ficient to abolish cleavage. It is possible that the mutation 
simply did not produce enough of a change to render the IG-
FBP-4 completely insensitive to cleavage at or around that site 
and that the His-121-Met-122 bond served as an alternate site. 
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FIG. 4. Inhibition of proteolysis by synthetic p eptides. Pure 
IGFBP-4 was incubated for 16 h at 37 · C with protease-containing 
media and 0.5 mglml syn thetic peptide. Lanes labeled 1-3 contain 
pep tides 1-3, respectively (see Fig. 3). C indicates control (no added 
peptide). 
It is also possible that the primary cleavage site is not between 
amino acids 120 and 121 but a few residues toward the COOH 
terminus and that processing by a carboxypeptidase removes 
additional amino acids to produce the large NH2-terminal frag-
ment. Indeed, there are many basic amino acids between resi-
dues 120 and 132, indicating several potential cleavage sites. 
Although it is possible that initial cleavage occurs as distal as 
residues 132-134, that seems unlikely since the 125- 135 syn-
thetic peptide had no effect on proteolysis. A third possibility is 
that more than one IGFBP-4 protease in B104 cell media may 
produce the fragments. Because the major fragments observed 
by ESMS are not contiguous, proteolysis must occur at least at 
two points in the molecule. 
The exact relationship between the protease found in the 
media of B104 cells and that described in other systems is not 
yet clear. The enhancing of proteolytic cleavage by IGF-1 is 
similar to that described for human and sheep fibroblasts (10, 
11), human decidua (16), vascular smooth muscle cells (25), and 
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FIG. 5. Immunoblot of nat ive (WT) and mutant (M UT) IGFBP-4 
following exposure to protease. Pure peptides were incubated with 
protease containing media in the presence or absence of IGF-I as de-
scribed under "Experimental Procedures" and analyzed on SDS-poly-
acrylamide gel electrophoresis followed by immunoblotting and chemi-
luminescent detection. I n this experiment 100 ng of IGFBP-4 were 
incubated with 50 p,l of media in a total reaction volume of60 p,l. Bands 
at the top of each gel represent intact IGFBP-4 while those near the 
bottom are the 16-kDa fragment. Time of exposure to the protease is 
indicated at the bottom. 
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FIG. 6. Top, comparison of proteolytic degradation of native (WT) and 
mutant IGFBP-4 (MUT) assessed by ligand blot. Pure peptides were 
exposed to the protease-containing media and IGF-I and sampled at the 
times indicated. In t his experiment 100 ng of IGFBP-4 were incubated 
with 50 p,l of media on a total reaction volume of 60 p,l. Bottom, 
PhosphorImage analysis ofthe ligand blot data. The experiment shown 
in the top panel was analyzed using the PhosphorImaging system with 
the numeric data plotted as percent of control (value at t = 0). The data 
for the N-glycosylated form of IGFBP-4 was derived by analysis of the 
less intense 28-kDa band observed just above the wild type IGFBP-4 
band. 
osteoblasts (18, 19). In our original description of the B104 cell 
protease, the addition ofIGF-I was not required to demonstrate 
proteolysis (21), but we believe that this is because the B104 
cells secrete small amounts of IGFs.2 The response to various 
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FIG. 7. Th e effec t of cleaved (16 kDa) IGFBP-4 and native IG-
FBP-4 on IGF-I -stimulated thymidine (TdR UP TAKE). Leftward 
bars indicate thymidine uptake in the absence of added IGFBP-4 with 
and without (control ) added IGF-l. Experiments with IGFBP-4 (as 
indicated) are in presence of 5 nglml IGF-l. Numerals within bars 
indicate concentration of added IGFBP-4 (ng/ml). 
protease inhibitors has been similar, but not identical, among 
the proteases even though proteolytic fragments produced by 
each appear to be of similar sizes. The protease studied here 
may be the rat homologue of the IGFBP-4 protease found in 
other species, but there may be m ultiple IGFBP-4 proteases as 
well. 
In a prior publication (21) we found that proteolytically 
cleaved IGFBP-4 could bind IGFs with an affinity that was 
reduced approximately 15-fold. Since the affinity of IGFBP-4 
for IGF-I is approximately 1 log order higher than the affinity 
of the receptor for IGF-1 (27, 28), such a change might be 
predicted to abrogate the inhibitory properties of IGFBP-4, as 
was found in our experiments . This is in accord with prior 
reports showing that, in other systems, the growth inhibitory 
properties of IGFBP-4 are lost following exposure to the prote-
ase (10, 20). 
Although the proteolytic processing ofIGFBP-4 is likely to be 
an important mechanism regulating IGFBP-4 and IGF action, 
many questions remain. It is not known whether the 16-kDa 
IGFBP-4· IGF complex retains any activity and whether the 
complex can be bound by the IGF-I receptor as a functional 
unit. Whether any of the IGFBP-4 cleavage products have 
functions independent of the IGFs is also unknown. Neverthe-
less, a plausible scenario for the physiologic role of the IGFBP-4 
protease might be as follows. The IGFBP-4 protease is induced 
or activated when IGF action is needed. The protease is specific 
for IGFBP-4 and preferentially attacks IGFBP-4 that is com-
plexed with an IGF. Cleavage ofIGFBP-4 releases sequestered 
IGFs and allows them to act on neighboring responsive cells, 
thereby providing a mechanism for directing the paracrine/ 
autocrine actions of the IGFs. 
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Note Added in Proof-Subsequent to the submission of this work 
Conover et al. (Conover, C. A., Durham, S. K., Zapf, J ., Masiarz, F. R. & 
Kiefer, M. C. (1995) J . BioI. Chem. 270, 4395-4400) described the 
cleavage of human IGFBP-4 by an IGFBP-4 protease. A fragment of 
IGFBP-4 was isolated that appeared to be homologous to the COOH-
terminal fragment we identified. Mutations in the vicinity of the site 
equivalent to residues 132-134 of rat IGFBP-4 were associated with 
some reduction in protease sensitivity, suggesting that this region of 
IGFBP-4 might a lso be involved in the cleavage process. 
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